Background: Anti-glycan antibodies can be found in autoimmune diseases. IgM against glycan P63 was identified in clinically isolated syndromes (CIS) and included in gMS-Classifier2, an algorithm designed with the aim of identifying patients at risk of a second demyelinating attack.
Introduction
Evidence exists that both the number of lesions observed using baseline magnetic resonance imaging (MRI) [1, 2] and the presence of IgG oligoclonal bands (OCB) in the cerebrospinal fluid (CSF) [3] [4] [5] of patients with clinically isolated syndromes (CIS) are independent predictors of conversion to clinically definite multiple sclerosis (CDMS). However, MS is a highly heterogeneous disease, and the search for other biomarkers that could improve the prediction of conversion to CDMS may still be necessary for early and appropriate therapeutic decision making [6, 7] .
A complex array of covalently attached glycans densely covers the surface of all cells and many proteins, and these molecules are a major component of the extracellular matrix. Thus, glycans are a prime antigen source and play a vital role in immunity. Indeed, antibodies against these molecules have been implicated in a number of autoimmune diseases [8] , for example, those directed against galactose in collagen type II in rheumatoid arthritis [9] , ganglioside GQ1b in Miller-Fisher syndrome [10] and oligomannose, mannobioside, laminaribioside, chitobioside, laminarin and chitin epitopes in Crohn's disease [11, 12] . IgM antibodies directed against glycans composed of alpha-glucose disaccharides have been found in MS patients and demonstrated to distinguish relapsing-remitting MS patients from those with other neurological diseases [13] [14] [15] . One of the identified antibodies was directed against P63, a polymer of alpha-glucose molecules comprising two different carbohydrate structures [Glc(al,6)Glc(a) and Glc(al,3)Glc(a)]. Thus, a classification rule named gMS-Classifier2, which is based on the combination of polyclonal serum IgM antibody levels against P63 and age, was developed after an exploration analysis of clinical data and anti-glycan antibody levels in samples collected in the ''BetaferonH in Newly Emerging multiple sclerosis For Initial Treatment'' (BENEFIT) trial. In this study, this classification rule identified CIS patients at higher risk of converting to CDMS during the first two years of disease evolution [16] . To validate these preliminary results, herein we aimed to analyze the gMS-Classifier2 predictive value for early conversion of CIS patients to CDMS and to determine whether gMS-Classifier2 is an independent predictor of conversion to CDMS. The present study is based on longitudinal clinical, CSF, serum and MRI data prospectively acquired from a cohort of CIS patients which started in 1995. Patients presenting for the first time with monophasic neurologic symptoms of the type seen in MS were recruited at the Vall d'Hebron University Hospital in Barcelona, Spain. Inclusion criteria were as follows: a CIS suggestive of central nervous system (CNS) demyelination involving the optic nerve, brainstem, spinal cord or other topography that were not attributable to other diseases; age ,50 years; and onset of symptoms within three months of both clinical and MRI examinations. Patients were seen every three to six months and if relapses occurred. IgG OCB were examined using agarose isoelectric focusing combined with immunoblotting. The remaining biological samples were stored at 280uC until testing. Brain MRIs were performed after the first demyelinating event and repeated after twelve months and five years of follow-up. From 2001 onwards, baseline cranial MRIs were performed at three months after the first demyelinating event. Further clinical, CSF and MRI assessments have been detailed elsewhere [1] .
Patients and Methods

Ethics Statement
Cases were selected from the CIS cohort based on the following eligibility criteria: consecutive patients older than 18 years of age seen between 1995 and 2007, with a minimum of two available 200 mL stored serum aliquots that had not undergone previous thawing.
A diagnosis of conversion to CDMS was made when new symptoms occurred after an interval of at least one month and only when other diagnoses had been excluded [17] . Time of follow-up was calculated based on the difference between the date of the baseline visit and the date of the last visit. De-identified and coded serum samples obtained at the time of enrolment in the department-wide sample repository were shipped to Glycominds, Ltd. (Modi'in, Israel) for analysis. Clinical data were not shared with collaborators at Glycominds until after the results of the serological analysis had been returned.
Serum samples were thawed according to the following protocol to prevent IgM precipitation: i) Samples were allowed to reach room temperature; ii) Samples were incubated at 37uC for 2 hours; iii) Samples were vortexed to homogeneity. IgM antibody measurement is stable if these conditions are met for no more than two freeze-thaw cycles.
Levels of anti-P63 IgM antibodies were measured in IgGdepleted serum samples by enzyme immunoassay (EIA) in duplicate. Briefly, microtiter 96-well plates with immobilized P63 were prepared as described elsewhere [18] . IgG was depleted from the samples using rheumatoid factor removal reagent (Chemicon, Australia, Cat. RFRR) according to the manufacturer's instructions. Following IgG removal, serum samples (using a dilution of 1:600 instead of the 1:1200 originally described) were dispensed into microtiter wells in duplicate, incubated for 180 minutes at 4uC, and washed with wash buffer. Bound antibodies were labelled with horseradish peroxidase (HRP)-conjugated goat anti-human IgM antibody, washed, and 3, 39, 5, 59-tetramethylbenzidine was added for detection. After 30 minutes, the enzymatic reaction was stopped by adding 1% sulphuric acid solution to the wells, and the optical density (OD) was read at 450 nm using a Victor 1420 plate reader (Wallac, Turku, Finland). Each plate included a 5-point calibration curve. Anti-P63 serum levels were reported in arbitrary EIA units (EU). gMS-Classifier2 units were calculated according to the following algorithm: [1.171 2 0.0826age in years at the time of blood collection]+[0.015 6 anti-P63 (EU)]. The gMS-Classifier2 was considered positive when the number of units was equal to or greater than 0.289 [16, 19] .
Statistical Analysis
Parametric and nonparametric comparative statistics were performed depending on the normality of the distributions of the continuous variables. Fisher's exact test was performed to compare categorical variables. Kaplan-Meier analysis was used to estimate cumulative survival probabilities and to construct survival plots. To assess whether gMS-Classifier2 can independently predict time to CDMS, a multivariate analysis using Cox proportional hazard regression was performed for both gMS-Classifier2 status (positive or negative) and continuous values. Baseline MRI parameters such as number of Barkhof Criteria (BC), the number of T2 lesions (0, 1-9, .9 lesions) and OCB were considered as potentially relevant covariates. Age was already included in the gMS-Classifier2 algorithm as a covariate; the role of gender and CIS topography as possible covariates was also evaluated. Time to event analysis was performed primarily at two years; it was additionally assessed at five years and total time of follow-up to evaluate the length of time during which the biomarker could be useful. To assess the clinical utility of gMS-Classifier2, a Hosmer and Lemeshow goodness-offit test was performed as a calibration measure for two models: one with number of Barkhof criteria, OCB and gMS-Classifier2; and one for number of T2 lesions, OCB and gMS-Classifier2. As discrimination measures, two ROC curve analyses were made: one model using number of Barkhof criteria, OCB and gMSClassifier2 continuous units and compared with a model without OCB. The second ROC curve analysis compared one model using number of T2 lesions, OCB and gMS-Classifier2 continuous units versus another in which OCB were excluded. Statistical tests were performed at the 0.05 level of significance using the Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL, USA) version 17.0.
Results
Between 1995 and 2007, 723 patients were included in the CIS cohort. gMS-Classifier2 units were determined in a subgroup of 249 (34%) patients that met the present study's selection criteria. The screened cohort was similar to the non-screened cohort in age, follow-up time, and proportion of both positive OCB and baseline number of Barkhof criteria. There were differences in the proportion of females and the topography of disease presentation (Table 1) . When comparing the demographic variables between patients with positive and negative gMS-Classifier2 status, including median time of follow-up, there was a difference in the proportion of females and in the distribution of CIS topography, but since the gMS-Classifier2 hazard ratio (HR) estimate was not substantially modified when gender or topography were included in the model, it was not considered necessary to adjust the results for these clinical variables (data not shown). There was also a difference in the median time of follow-up; however, as it was of approximately 5 months between groups, it was not considered relevant when the total follow-up time was of up to 14 years.
gMS-Classifier2 Status at Specified Time Points and Conversion to CDMS
The median value of gMS-Classifier2 was 20.24 units (range 22.3 to 5.5 units) and seventy-five patients (30.1%) were positive for gMS-Classifier2.
The median time to CDMS was 37.8 months for gMSClassifier2-positive patients (95%CI 10.4-65.3 months) and 83.9 months (95%CI 57.5-110.5) for gMS-Classifier2-negative patients. gMS-Classifier2 predicted conversion to CDMS within two years (HR = 1.8, 95%CI 1.1-2.9; p = 0.013) and within five years of follow-up (HR = 1.5, 95%CI 1.0-2.4; p = 0.033) but not for total follow-up time, although a trend was observed (HR = 1.4, 95%CI 1.0-2.2; p = 0.060) (Figure 1 ). Table 2 shows the proportion of CDMS patients that were positive and negative for gMSClassifier2 at 2 years, 5 years and total time of follow-up.
Predictive Value of gMS-Classifier2 Status for Conversion to CDMS
In a univariate analysis, gMS-Classifier2 status (positive/ negative), Barkhof criteria, number of T2 lesions and presence of OCB were predictors for early conversion to CDMS at two years of follow-up (Table 3 ).
In the multivariate analyses at two years of follow-up, gMSClassifier2 status remained significant when tested with number of Barkhof criteria (HR = 1.8, 95%CI 1.1-2.8, p = 0.014) or number of T2 lesions (HR = 1.7, 95%CI 1.1-2.7, p = 0.020). When combining gMS-Classifier2 status and OCB, the formers significance was lost (HR = 1.5, 95%CI 0.9-2.4, p = 0.095). When combining gMS-Classifier2 status with OCB and either Barkhof criteria or number of T2 lesions the HR were non-significant (HR 1.5, 95%CI 0.9-2.5, p = 0.081 and HR 1.5, 95%CI 0.9-2.4, p = 0.100, respectively) ( Table 4) . When adding treatment to these models, there were no statistically significant changes in the HR of gMS-Classifier2 (data not shown). In the univariate analysis, gMS-Classifier2 continuous units, Barkhof criteria, number of T2 lesions and presence of OCB were predictors for early conversion to CDMS at two and five years of follow-up (Table 3 ).
In the multivariate analyses at two years of follow-up, gMSClassifier2 continuous units remained significant when tested with number of Barkhof criteria (HR = 1.3, 95%CI 1.1-1.5, p = 0.003) or number of T2 lesions (HR = 1.3, 95%CI 1.1-1.6, p = 0.001).
When combining gMS-Classifier2 continuous units and OCB, the formers significance was lost (HR = 1.1, 95%CI 0.9-1.4, p = 0.088), but when combining gMS-Classifier2 continuous units with OCB and either Barkhof criteria or number of T2 lesions the HR were once again statistically significant (HR 1.2, 95%CI 1.0-1.5, p = 0.020 and HR 1.3, 95%CI 1.1-1.5, p = 0.008, respectively) (Table 5 ).When adding treatment to these models, there were no statistically significant changes in the HR of gMS-Classifier2 (data not shown). Table 2 . gMS-Classifier2 status and number of patients converting to CDMS at specified time points. Similar results were obtained at five years of follow-up in the uni-and multivariate analyses for gMS-Classifier2 status and continuous units (Tables 3, 4 and 5). At total time of follow-up, gMS-Classifier2 status and continuous units were not predictive of conversion to CDMS in the univariate analysis (Table 3) , but when included in the multivariate models, gMS-Classifier2 continuous units remained independent predictors except when combined with OCB, whereas gMS-Classifier2 status yielded mostly negative results (Tables 4 and 5 ).
Discrimination Measures: ROC Curve Analyses
To assess the clinical utility of gMS-Classifier2, the calibration measures for number of Barkhof criteria, OCB and gMSClassifier2 continuous units yielded a p value of 0.303; and the one performed for number of T2 lesions, OCB and gMSClassifier2 continuous units showed a p value of 0.664. When performing the ROC analyses as discrimination measures, in the model using number of Barkhof criteria, the ROC association 
Discussion
Early administration of disease modifying therapies is highly recommended in CIS patients at risk for developing a second relapse [20, 21] . Therefore, although MRI remains the most important surrogate marker for predicting the risk of a second relapse in CIS patients [1, 2] , the clinical outcome remains unpredictable due to the high variability of this disease among individuals. Thus, a need remains for auxiliary biomarkers that could provide additional information about the disease course [22, 23] . The presence of IgG OCB at baseline doubles the risk of developing a second attack independent of MRI, but in the revised 2010 diagnostic criteria for MS, CSF was only included in the diagnostic criteria for primary progressive MS. Thus, the testing of CSF may further decline, despite the fact that the International Panel agrees that the inclusion of CSF in the criteria requires further evaluation [5, 23] . Furthermore, an ideal biomarker should be non-invasive and simple to use, making potential serum prognostic markers a good option, as they would be easy to obtain [24] .
Glycans are potential antigens, and indeed, antibodies against various types of glycans have been found in serum. Such antibodies were first described for the human blood group ABO antigens [25] , and later findings have linked antibodies directed against glycans to several autoimmune diseases, either by association only or as etiopathogenic [8] [9] [10] [11] [12] . Consequently, diverse assays have been designed to identify anti-glycan antibodies in autoimmune diseases [18, 26] including MS [27] [28] [29] . Because some of these glycans are found within the type IV collagen matrix of the blood-brain barrier [14] , it has been hypothesized that in MS patients, an inflammatory response could lead to the release of these carbohydrate antigens with the subsequent development of a humoral response [30] . Therefore, an array of glycans was screened in RRMS patients and healthy controls, observing that IgM antibodies to various alpha-glucose are elevated in the former group. Among the alpha-glucose, GAGA4 was the most notable and gMS-Classifier Dx was developed as GAGA4 normalized to total IgM. It was further analysed with other neurological diseases controls (13, 31) , concluding that gMS-Classifier Dx differentiates between MS and non-MS patients. Based on previous experience in Crohn's disease in which broader glycan structures increase performance and address different clinical utilities, gMS-Classifier Dx was extended to include the following anti-alpha glucose antibodies: GAGA2, 3, 4 and 6, thus establishing gMS-Classifier1, which is based on disaccharides covalently bound via a long linker (anti-GAGA2, anti-GAGA3, anti-GAGA4, anti-GAGA6) and was established for the prediction of ''early relapse'' (within 24 months) (14) . Then, in the BENEFIT study, gMS-Classifier1 was analysed on three pre-defined end-points: 1) Time to CDMS, 2) Time to McDonald, and 3) Time to confirmed EDSS. However, Classifier1 was only significant on Time to confirmed EDSS (16, 32) . Thus, Classifier1 seems to be more of a prognostic MS biomarker for progression rather than for diagnosis. As part of the BENEFIT study, several additional alpha-glucose antibodies were analysed due to previously found data that suggested it could be beneficial to further explore them and see their potential value. Among those additional alpha-glucose antibodies were P63, [a polymer based on Glc(a1-3)Glc(a) and Glc(a 1-6)Glc(a)], alpha-ramose, alpha-Nacetyl glucose and P64 [(a polymer based on Glc(a 1-4)Glc(a) and Glc(a 1-6)Glc(a)]. For each one, time to CDMS with a minimal criterion of 30% sensitivity and 90% specificity at 24 months was analysed in the BENEFIT placebo sub-cohort and on the entire cohort. Only P63 normalized to age predicted time to CDMS and it was called gMS-Classifier2 (16) .
A logistic regression model for prediction of early conversion to CDMS was used to develop the classifier; the input data included a number of clinical variables such as age since previous data have shown that IgM levels vary considerably throughout the years [33, 34] , plus the raw levels of anti-glycan IgM against 8 different glycan antigens. After backward selection only anti-P63 IgM levels and age were found to be independent variables which entered the model. Since this classification rule identified CIS patients at higher risk of converting to CDMS during the first two years of disease evolution [16] , the aims of the present study were to confirm those results and to determine whether gMS-Classifier2 is an independent predictor of conversion to CDMS.
Our results show that in this hospital cohort, gMS-Classifier2 is an independent predictor for conversion of CIS patients to CDMS that could become a useful prognostic tool when tested within the first two years of disease evolution, and thus could add information to baseline MRI findings, more specifically, in cases in which lumbar puncture or OCB determination cannot be performed. gMS-Classifier2 was positive in 30% of CIS patients at baseline, and the median time to CDMS was approximately twice as short for gMS-Classifier2-positive patients than for negative patients. The predictive performance of gMS-Classifier2 was better during the early years of the disease and decreased with long-term followup. When gMS-Classifier2 status was evaluated together with MRI variables in the multivariate analyses at two and five years of follow-up, it remained an independent predictor of conversion to CDMS, but not when evaluated with OCB. With MRI and OCB findings, continuous unit values of gMS-Classifier2 independently predicted the development of an early second relapse, indicating the increased risk of relapse with increased serum levels of the biomarker. When performing the ROC analyses, the model for gMS-Classifier units was statistically significant only when OCB were excluded. However, recent publications emphasize that testing for any improvement using discrimination measures such as the change in the area under the ROC curve is extremely conservative [36, 37] . Thus, we consider the HRs to be sufficient to support the role of gMS-Classifier2 as an independent predictor of conversion to CDMS.
As for the added value of gMS-Classifier2 to OCB findings in predicting early CDMS conversion, the differing results obtained are probably partly due to the higher resolution of a biomarker that is measured in continuous units compared to a dichotomous biomarker [35] .
We conclude that gMS-Classifier2 is an independent predictor for conversion of CIS patients to CDMS in the first years of the disease course and therefore could be of clinical relevance to determine which patients are at higher risk, particularly in cases in which OCB are not available.
